KOSDAQBiotech & Pharma347740

P&K Skin Research Center

₩1,812▲ 0.33%2026-11-18 close
Market Cap
₩54.4B
Turnover
₩8,564,980
Volume
4.8K
Shares out.
30M
PER
19.4×
PBR
0.6×
EPS
₩93
Dividend Yield
2.77%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Orders and sales growing; margin recovery is the test

Revenue has risen for four straight quarters from Q4 2025 through Q3 2026, and the order backlog reached KRW 8.6 billion at end-Q3 2026, but the 2025 operating margin of 17.3% remains below the company's 20% target, making margin recovery the key test.

  1. 1

    2025 revenue reached KRW 22.8 billion, up 27.7% year on year, the largest year in the 2022–2025 span.

  2. 2

    Q3 2026 revenue of KRW 6.76 billion grew 33.8% from a year earlier, extending a run of four consecutive quarterly increases.

  3. 3

    Cosmetic human-application testing accounts for 81% of nine-month revenue, and the backlog at end-Q3 2026 rose 59% year on year to KRW 8.6 billion, per reporting on the November 16, 2026 disclosure.

  4. 4

    The operating margin fell from 31.4% in 2022 to 9.3% in 2023 and recovered to 17.3% in 2025, still short of the 20% annual target the company set.

  5. 5

    Controlling-shareholder net income swung sharply, from a net loss of KRW 877 million in Q4 2025 to KRW 579 million in Q3 2026.

02

Business structure

P&K Skin Research Center (P&K Skin Research Center) conducts human-application testing for cosmetics, health functional foods and beauty devices, along with in-vitro testing. The company describes itself as the largest skin human-application testing specialist in Korea.

In the nine months through Q3 2026, cosmetic human-application testing generated KRW 15.9 billion, or 81% of revenue, up about 12% year on year, according to reporting on the November 16, 2026 disclosure.

Demand in this segment comes from Korean cosmetic brands expanding overseas, which increases requests for efficacy verification. Rising hair-care exports have also lifted demand for scalp and hair testing.

The customer base spans indie brands, mid-sized brands and large companies, and the company cites new orders from a wider indie-brand lineup as a growth driver.

Health functional food testing has scaled up through a research center the company has been building since 2021; the company said that segment's revenue rose 486% year on year in Q1 2025.

Its capabilities extend from OCT and Raman spectroscopy measurement to custom protocol design and data analysis such as the Skin Aging Index. Its color-cosmetics subsidiary plans to supply products from projects with US and European brands starting in the first half of 2027.

On regulatory work, the company began FDA product registration agency services and global regulatory consulting in 2025. The company positions itself as a partner that carries testing through product development and data use, rather than only delivering results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.1B₩500M8.9%
2025Q4₩5.8B₩800M13.0%
2026Q1₩6.2B₩1B15.4%
2026Q2₩6.6B₩1.5B22.9%
2026Q3₩6.8B₩1.2B17.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩18B₩5.6B₩7.1B31.4%10.1%5.3%
2023₩14.8B₩1.4B₩4.7B9.3%6.3%4.3%
2024₩17.8B₩2.6B₩5.8B14.5%7.6%6.7%
2025₩22.8B₩3.9B₩4.7B17.3%5.8%7.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 18 billion in 2022 to KRW 14.8 billion in 2023, down 17.3%, then rose to KRW 17.8 billion in 2024 (up 20.2%) and KRW 22.8 billion in 2025 (up 27.7%), growing for two consecutive years after 2023. 2025 was the largest year of the 2022–2025 span, and the company said its 2025 revenue was the highest since its founding.

Operating profit dropped from KRW 5.64 billion in 2022 to KRW 1.38 billion in 2023 (down 75.6%), then rose to KRW 2.58 billion in 2024 (up 87.3%) and KRW 3.94 billion in 2025 (up 52.6%), increasing for two consecutive years after 2023.

The operating margin fell from 31.4% in 2022 to 9.3% in 2023 and has recovered to 14.5% in 2024 and 17.3% in 2025, but it has not returned to the 2022 level. Against the company's disclosed target of an operating margin of at least 20% each year from 2026 to 2028, the 2025 figure is still below.

Controlling-shareholder net income was KRW 7.13 billion in 2022, KRW 4.7 billion in 2023 (down 34.1%), KRW 5.82 billion in 2024 (up 23.7%) and KRW 4.69 billion in 2025 (down 19.4%). Net income including non-controlling interests, which is a different figure, was KRW 4.6 billion in 2025.

In the first half of 2026, operating profit fell about KRW 300 million year on year, which the company attributed to higher personnel costs, depreciation on test equipment and expenses from expanding its subsidiary business, per reporting dated August 18, 2026.

Quarterly revenue went from KRW 5.05 billion in Q3 2025 to KRW 5.78 billion in Q4 2025 (up 14.3% quarter on quarter), KRW 6.24 billion in Q1 2026 (up 7.9%), KRW 6.59 billion in Q2 2026 (up 5.7%) and KRW 6.76 billion in Q3 2026 (up 2.5%), rising for four consecutive quarters from Q4 2025 through Q3 2026; Q3 2026 revenue was up 33.8% year on year.

Quarterly operating profit rose from KRW 452 million in Q3 2025 to KRW 752 million in Q4 2025, KRW 959 million in Q1 2026 and KRW 1.51 billion in Q2 2026, then fell 20.0% quarter on quarter to KRW 1.21 billion in Q3 2026.

In Q1 2026, some health functional food projects were delayed, which pushed back revenue recognition; revenue fell 3.4% and operating profit fell 49.8% year on year, per reporting on the May 15, 2026 disclosure.

Controlling-shareholder net income swung from a net loss of KRW 877 million in Q4 2025 to a profit of KRW 1.49 billion in Q1 2026, then fell to KRW 579 million in Q3 2026, down 62.1% quarter on quarter and 63.7% year on year.

Net income attributable to controlling shareholders over the last four quarters totaled KRW 2.72 billion. Preliminary nine-month figures announced on November 16, 2026 showed revenue of KRW 19.6 billion and operating profit of KRW 3.7 billion, each up about 15% year on year.

Quarterly swings in profit appear to depend heavily on the timing of project schedules and the spending on staff and equipment.

05

Industry analysis

Demand for the company's testing is directly tied to Korean beauty products expanding overseas. The company said efficacy-related human testing requests rose as Korean cosmetic brands expanded abroad.

Citing Korea Customs Service trade statistics, reporting said shampoo exports in Q3 2026 reached USD 70.11 million, up 46.6% from USD 47.82 million a year earlier.

Faster launch cycles at indie brands and wider global distribution are cited as drivers of demand for efficacy and advertising substantiation, per reporting dated August 2026.

On regulation, the company argues that Korea's 2026 guideline for cosmetic safety evaluation documentation has raised the importance of safety substantiation. The seasonal pattern is also shifting: the company said cosmetic testing revenue, traditionally concentrated in Q4, held up in Q1 2026, easing seasonality.

The segment is more sensitive to brand launches and export flows than to the broader business cycle. Competitively, the company emphasizes its measurement-based evaluation using OCT and Raman spectroscopy and its data interpretation system.

Unlike biopharma companies such as Samsung Biologics or Celltrion, which depend on drug pipelines, the key indicators here are order flow and customer diversification. For overseas markets, the company's April 2026 disclosure set out plans to win more human-testing orders in Japan, Southeast Asia and Europe. Its health-care expansion plan also covers health functional foods, beauty devices and wearable devices.

06

Outlook

In its April 1, 2026 corporate value-up plan, the company set targets of average annual revenue growth of at least 20% over 2026–2028 and an operating margin of at least 20% in each year, and it pledged to maintain high-dividend status by government criteria as a shareholder return goal.

The 2025 revenue growth of 27.7% exceeded the 20% growth target, while the 2025 operating margin of 17.3% fell short of the 20% margin target. The order backlog at end-Q3 2026 was KRW 8.6 billion, up 59% year on year, and the company plans to convert these orders into Q4 2026 revenue according to test schedules.

The backlog has also risen from KRW 6 billion at end-Q1 2026 to KRW 8 billion at mid-2026. Its color-cosmetics subsidiary plans to supply products from projects with US and European brands starting in the first half of 2027.

The company said it will pursue a larger overseas revenue share and better profitability at the same time. The company expects profitability to improve gradually as delayed health functional food project revenue is recognized, per reporting from May 2026.

However, operating profit fell quarter on quarter in Q3 2026, and the key question is how quickly the staff and equipment added in the first half translate into revenue. Q4 2026 revenue and the full-year operating margin will first be visible in preliminary annual results in early 2027. Whether the backlog converts into Q4 2026 revenue is the first indicator of whether the targets are on track.

07

Valuation

PER
19.4×
PBR
0.6×
ROE
3.3%
EPS
₩93
BPS
₩2,862
Dividend per share
₩50

The share price trades below the company's book net asset value. Total equity at end-2025 was KRW 80.5 billion, with controlling-shareholder equity of KRW 80.6 billion, so market capitalization sits below the net asset base.

On earnings, net income attributable to controlling shareholders totaled KRW 2.72 billion over the last four quarters, which is small relative to the asset base, so the earnings multiple reflects quarterly swings strongly.

Controlling-shareholder net income was KRW 4.69 billion in 2025, down from 2024, and KRW 579 million in Q3 2026, down 63.7% year on year. Operating profit has recovered for two consecutive years after the 2023 low.

The company has set a high-dividend target, so operating cash flow matters for shareholder returns; it fell from KRW 9.03 billion in 2024 to KRW 6.68 billion in 2025. The debt-to-equity ratio of 7.5% at end-2025 indicates a light financial burden.

The largest shareholder and related parties held 59.41% per the September 2025 ownership data, which limits the number of freely traded shares and affects trading characteristics. Even within the biopharma sector, the earnings structure differs from drug developers, so direct multiple comparisons are difficult.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Four straight quarters of revenue growth

Quarterly revenue rose for four consecutive quarters from Q4 2025 through Q3 2026. Q3 2026 revenue of KRW 6.76 billion grew 33.8% year on year. The company said nine-month revenue of KRW 19.6 billion was the highest for that period, per reporting on the November 16, 2026 disclosure.

Expanding order backlog

The backlog at end-Q3 2026 was KRW 8.6 billion, up 59% from KRW 5.4 billion a year earlier. It followed KRW 6 billion at end-Q1 2026 and KRW 8 billion at mid-2026. The company plans to convert these orders into Q4 2026 revenue according to test schedules.

Low leverage and a shareholder-return target

Total liabilities at end-2025 were KRW 6.04 billion, and the debt-to-equity ratio was 7.5%. Total equity was KRW 80.5 billion. In its April 2026 corporate value-up plan, the company stated a goal of keeping high-dividend status by government criteria.

09

Bear factors

Gap to the operating margin target

The 2025 operating margin of 17.3% was below the 31.4% of 2022 and short of the company's target of at least 20% a year for 2026–2028. Q1 2026 operating profit fell 49.8% year on year as staffing, depreciation, subsidiary costs and deferred projects weighed. Q3 2026 operating profit of KRW 1.21 billion fell 20.0% quarter on quarter.

Volatility in controlling-shareholder net income

Controlling-shareholder net income was KRW 4.69 billion in 2025, down 19.4% year on year. Q4 2025 posted a net loss attributable to controlling shareholders of KRW 877 million. Q3 2026 net income of KRW 579 million was down 63.7% year on year, showing large quarter-to-quarter swings.

Project timing and customer concentration

In Q1 2026, some health functional food projects were delayed, pushing back revenue recognition. Cosmetic testing makes up 81% of revenue, so results depend heavily on demand from Korean beauty brands.

Product supply from the color-cosmetics subsidiary is scheduled for the first half of 2027, so the results of this new business should show up from 2027 onward.

10

Risk factors

Export and brand-demand risk

Testing demand depends on K-beauty export flows and the launch cycles of indie brands. Shampoo export growth in Q3 2026 supports demand, but a change in export conditions could reduce testing requests.

The company says it is not dependent on any single brand's success, yet concentration of verification demand in one market and one industry remains a variable.

Cost growth and profitability

Higher research-staff costs, equipment depreciation and expenses from subsidiary expansion mean revenue growth is not flowing directly into operating profit. Reaching the 20% operating margin target requires both revenue expansion and cost control. Because costs rise first and revenue follows project timing, quarterly profit tends to swing.

Liquidity and ownership structure

As of the September 2025 ownership data, the largest shareholder and related parties held 59.41%, which limits the number of freely traded shares. As a small-cap stock, price moves can be larger when trading volume is thin.

If the subsidiary's overseas projects do not start in the first half of 2027 as planned, the pace of the overseas revenue expansion would also slow.

11

What to watch next

  1. Late February 2027

    Preliminary full-year 2026 results are due (the 2025 annual results were disclosed on February 26, 2026). Check whether annual revenue growth met the 20% target, how close the operating margin came to 20%, and how much of the KRW 8.6 billion backlog at end-Q3 2026 converted into Q4 revenue.

  2. Late March 2027

    The 2026 annual business report is due. Confirmed full-year figures for controlling-shareholder net income, operating cash flow and the debt-to-equity ratio will be fixed in the periodic report.

  3. Mid-May 2027

    Q1 2027 results are due. The Q1 2026 results were disclosed on May 15, 2026. Check whether delayed health functional food project revenue has been recognized and whether personnel and depreciation costs are easing.

  4. First half of 2027

    The planned start of product supply from the color-cosmetics subsidiary's projects with US and European brands. Check whether it links to the goal of a larger overseas revenue share.

12

Overall view

P&K Skin Research Center is a testing services company centered on cosmetic human-application testing, and its revenue growth trend is clear. 2025 revenue reached KRW 22.8 billion, up 27.7%, and quarterly revenue has risen for four consecutive quarters from Q4 2025 through Q3 2026.

The order backlog expanded to KRW 8.6 billion at end-Q3 2026. Profitability, however, is still recovering. The 2025 operating margin of 17.3% remains below the 31.4% of 2022 and short of the company's 20%-or-higher annual target for 2026–2028.

Q1 2026 operating profit fell 49.8% year on year on delayed health functional food projects and higher costs, and Q3 2026 net income attributable to controlling shareholders of KRW 579 million shows large quarterly swings.

On the financial side, a 7.5% debt-to-equity ratio and total equity of KRW 80.5 billion indicate ample financial capacity. Strengths and weaknesses coexist.

The next points to check are the operating margin in preliminary 2026 annual results, the confirmed figures in the 2026 annual business report, and how delayed project revenue and cost burdens show up in Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. view.asiae.co.kr
  2. supple.kr
  3. news.mtn.co.kr
  4. newspim.com
  5. comp.fnguide.com
  6. fnnews.com
  7. mt.co.kr
  8. cosinkorea.com
  9. v.daum.net
  10. pharmnews.com
  11. medipharmhealth.co.kr
  12. mt.co.kr
  13. newswire.co.kr
  14. news.nate.com
  15. newsis.com
  16. cosinkorea.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis